Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in moderate-to-severe atopic dermatitis
NL-OMON52453Phase 3Completed
- Sponsor
- Galderma
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nemolizumab in atopic dermatitis (AD) (6 arms), sponsored by Galderma. Primary endpoints: IGA success at Week 16 and EASI-75 at Week 16. Started Nov 2020; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON52453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52453.